DUBLIN, IRELAND – February 2, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), announced today that its Founder and Chief Scientific Officer, Prof. Therese Kinsella, PhD, MRIA, will deliver a corporate showcase presentation at the 2018 Biotech & Money / Medtech & Money World Congress in London, England, Tuesday, February 6, 2018 at 12:30 PM. The event will take place at etc.venues, St. Pauls.
For more information about the 2018 Biotech & Money / Medtech & Money World Congress, please refer to the conference website here.
About ATXA Therapeutics
Headquartered in Dublin, Ireland, ATXA Therapeutics Limited is a spin-out company from University College Dublin whose primary focus is to advance clinical trials and to secure marketing authorization of novel therapies for the treatment of Pulmonary Arterial Hypertension (PAH), serving a previously unmet medical need by offering improved treatment options to the prescribing physician and new hope for the PAH patient. Founded in May 2015, ATXA Therapeutics Limited is the culmination of over 20 years of extensive research and over €15m of grant funding and a proven track record in understanding of the biology and signalling of the human prostanoid receptors in the cardiovascular disease and oncology setting. For more information, please visit http://www.atxatherapeutics.com.
Press Contact: email@example.com